drugset / Trial / NCT07330648
Prospective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety Disorder
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A placebo-controlled superiority design was used to evaluate the efficacy of 40 mg/ day of Crisugabalin capsules in the treatment of GAD.
Timeline
- Start
- 2025-10-10
- Primary completion
- 2027-01-31
- Completion
- 2027-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HSK16149 | Unknown | 20 mg | Oral |
| Subject | Venlafaxine | Small molecule | 75 mg | Oral |